FDA advisers back GW’s Epidiolex for rare epilepsy
UK firm’s potential blockbuster on course for approval
X
FDA advisers back GW’s Epidiolex for rare epilepsy
https://pharmaphorum.com/news/fda-advisers-back-gws-epidiolex-for-rare-epilepsy/
epilepsy
GW prepares US for cannabis-based epilepsy drug
GW pushing for legal clearance in some states
GW files cannabis-based epilepsy drug in EU and US
After Sativex disappointment, Epidiolex could transform GW’s fortunes.
NeuroPace brain implant reduces epilepsy seizures in long-term trial
Data also suggests treatment could improve memory
UCB recruits Belgian wearables firm for epilepsy study
Byteflies’ Sensor Dot will help monitor brain, heart and respiration activity.
GW prepares for 2018 US launch of epilepsy drug
But Zynerba’s cannabis epilepsy drug fails in phase 2.
GW close to filing cannabis-based epilepsy drug
Epidiolex could become a blockbuster if approved in all uses.
Report links Sanofi epilepsy drug with thousands of birth defects
Depakine and generics linked with defects including spina bifida.
Novartis’ Votubia approved in childhood epilepsy
Votubia gets new indication.